These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31846627)

  • 21. Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics.
    Dunbar RL; Goel H; Tuteja S; Song WL; Nathanson G; Babar Z; Lalic D; Gelfand JM; Rader DJ; Grove GL
    J Lipid Res; 2017 Apr; 58(4):783-797. PubMed ID: 28119443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Langerhans cells release prostaglandin D2 in response to nicotinic acid.
    Maciejewski-Lenoir D; Richman JG; Hakak Y; Gaidarov I; Behan DP; Connolly DT
    J Invest Dermatol; 2006 Dec; 126(12):2637-46. PubMed ID: 17008871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
    Thakkar RB; Kashyap ML; Lewin AJ; Krause SL; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2009; 9(2):69-79. PubMed ID: 19331435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.
    Vosper H
    Br J Pharmacol; 2009 Sep; 158(2):429-41. PubMed ID: 19627285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pyrazole partial agonists on HCA(2) -mediated flushing and VLDL-triglyceride levels in mice.
    Li Z; Blad CC; van der Sluis RJ; de Vries H; Van Berkel TJ; Ijzerman AP; Hoekstra M
    Br J Pharmacol; 2012 Oct; 167(4):818-25. PubMed ID: 22616721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Niacin: an old drug rejuvenated.
    Kamanna VS; Ganji SH; Kashyap ML
    Curr Atheroscler Rep; 2009 Jan; 11(1):45-51. PubMed ID: 19080727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Niacin use and cutaneous flushing: mechanisms and strategies for prevention.
    Davidson MH
    Am J Cardiol; 2008 Apr; 101(8A):14B-19B. PubMed ID: 18375236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia.
    Keenan JM
    J Clin Lipidol; 2013; 7(1):14-23. PubMed ID: 23351578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.
    Ingersoll MA; Potteaux S; Alvarez D; Hutchison SB; van Rooijen N; Randolph GJ
    Immunobiology; 2012 May; 217(5):548-57. PubMed ID: 21798616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushing.
    Sakurai T; Davenport R; Stafford S; Grosse J; Ogawa K; Cameron J; Parton L; Sykes A; Mack S; Bousba S; Parmar A; Harrison D; Dickson L; Leveridge M; Matsui J; Barnes M
    Eur J Pharmacol; 2014 Mar; 727():1-7. PubMed ID: 24486398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With Dyslipidemia.
    Olson EJ; Mahar KM; Haws TF; Fossler MJ; Gao F; de Gouville AC; Sprecher DL; Lepore JJ
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):871-883. PubMed ID: 31268250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-guided engineering of biased-agonism in the human niacin receptor via single amino acid substitution.
    Yadav MK; Sarma P; Maharana J; Ganguly M; Mishra S; Zaidi N; Dalal A; Singh V; Saha S; Mahajan G; Sharma S; Chami M; Banerjee R; Shukla AK
    Nat Commun; 2024 Mar; 15(1):1939. PubMed ID: 38431681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standardized fraction of Xylocarpus moluccensis fruits improve vascular relaxation and plaque stability in dyslipidemic models of atherosclerosis.
    Kanshana JS; Rebello SC; Pathak P; Kanuri BN; Aggarwal H; Srivastava V; Khanna V; Singh V; Jagavelu K; Barthwal MK; Dikshit M
    J Ethnopharmacol; 2018 Mar; 213():81-91. PubMed ID: 29129602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.
    Lukasova M; Hanson J; Tunaru S; Offermanns S
    Trends Pharmacol Sci; 2011 Dec; 32(12):700-7. PubMed ID: 21944259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice.
    Inceoglu AB; Clifton HL; Yang J; Hegedus C; Hammock BD; Schaefer S
    J Cardiovasc Pharmacol; 2012 Jul; 60(1):70-5. PubMed ID: 22526297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
    Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
    J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective effects of lipoic acid-niacin dimers against blue light-induced oxidative damage to retinal pigment epithelium cells.
    Zou XL; Yu YZ; Yu HH; Wang GF; Pi RB; Xu Z; Zhang C; Zhou WJ; Li DD; Chen XG; Zou YP
    Int J Ophthalmol; 2019; 12(8):1262-1271. PubMed ID: 31456915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Future of GPR109A agonists in the treatment of dyslipidaemia.
    Wanders D; Judd RL
    Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
    Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.